GlaxoSmithKline opened a new $13 million research hub in London focused on artificial intelligence.

Working with a new class of drugs called G12C KRAS inhibitors, the Francis Crick Institute and Institute of Cancer Research developed product combos to stay ahead of drug-resistant tumors.